NeuroBo Pharmaceuticals, Inc. (NRBO)
NASDAQ: NRBO · Real-Time Price · USD
2.690
-0.010 (-0.37%)
Oct 8, 2024, 2:12 PM EDT - Market open

Company Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.

It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.

The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.

It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726.

NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Hyung-Heon Kim

Contact Details

Address:
545 Concord Avenue, Suite 210
Cambridge, Massachusetts 02138
United States
Phone 857 702 9600
Website neurobopharma.com

Stock Details

Ticker Symbol NRBO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001638287
CUSIP Number 64132R107
ISIN Number US64132R4048
Employer ID 47-2389984
SIC Code 2834

Key Executives

Name Position
Hyung-Heon Kim Chief Executive Officer, President and Director
Marshall H. Woodworth Chief Financial Officer
Dr. Mi-Kyung Kim Chief Scientific Officer
Robert Homolka Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Oct 7, 2024 8-K Current Report
Sep 30, 2024 8-K Current Report
Sep 20, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 19, 2024 8-K Current Report
Aug 21, 2024 DEF 14A Other definitive proxy statements
Aug 14, 2024 10-Q Quarterly Report
Aug 14, 2024 8-K Current Report
Aug 13, 2024 8-K Current Report
Aug 7, 2024 PRE 14A Other preliminary proxy statements
Aug 6, 2024 8-K Current Report